Unichem Lab Peer Comparison

NSE: UNICHEMLAB | BSE: 506690

₹564.25

₹24.50 (4.54%)

As on 28-Aug-2026IST

Market cap

₹3,971 Cr

Revenue (TTM)

₹1,394 Cr

P/E Ratio

23.9

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	3,971	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	1,394	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	166.32	1,018.97	497.77	603.02	270.18
Net Margin (%)	11.32	10.47	20.72	22.63	23.29
RoE (%)	-0.40	21.30	28.49	19.61	14.45
Price to Earnings	23.88	35.10	59.86	27.51	56.31
Price-To-Book	1.51	6.79	14.74	4.76	7.48

Income Statement (₹ Cr)

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	2,201.85	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	2,264.91	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	2,017.68	7,457.80	1,448.49	1,754.55	686.95
EBITDA	184.17	1,745.74	574.50	797.28	367.94
Depreciation	125.12	415.05	91.74	75.36	74.46
EBIT	59.05	1,330.70	482.76	721.93	293.48
Interest	31.59	143.67	23.95	5.37	0.82
Other Income	63.06	131.47	30.17	60.41	52.36
Exceptional Items	201.86	-31.35	76.40	-25.66	-3.28
Profit before Tax	292.38	1,287.14	488.98	751.31	344.65
Provision for Tax	39.54	345.87	124.98	186.83	85.42
Profit after Tax	252.84	941.27	364.00	564.48	259.23

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	2,717.44	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	--	26.64	--	--	-1.92
Non-Current Liabilities	103.50	584.19	345.47	142.73	47.58
Current Liabilities	885.94	3,912.24	710.20	682.24	169.08
Total Liabilities	3,706.88	9,514.48	2,930.14	4,157.10	2,231.79

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,506.29	3,861.01	1,447.01	1,333.54	981.68
Current Assets	2,197.34	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	3,706.88	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	468.78	1,204.08	196.61	0.00	0.00
Net Current Assets	1,311.40	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	125.64	258.92	13.18	4.82	3.76

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	3.64	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	192.06	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	1.86	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	197.56	93.92	-56.08	-69.08	11.28

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	10.68	25.25	27.50	24.61	18.04
ROE (%)	9.81	20.09	21.43	18.41	13.54
ROA (%)	6.97	10.70	14.25	14.27	12.15
EBIT Margin (%)	11.23	20.40	29.89	33.61	39.84
Net Margin (%)	11.16	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	17.17	14.44	22.53	24.81	31.63

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	4.31	16.56	36.98	6.91	-12.10
EBIT Growth (%)	-17.64	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	83.86	33.05	39.94	16.24	-30.25
EPS Growth (%)	83.86	35.59	39.94	16.05	-29.80
Book Value Growth (%)	10.88	11.36	22.95	18.43	11.27

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	8.18	32.73	42.34	21.18	40.73
Price / Book Value	0.76	6.13	8.23	3.60	5.27
Dividend Yield (%)	0.00	0.23	0.28	0.51	0.74
EV/EBITDA	9.07	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	2,067.98	30,257.56	15,412.11	11,956.86	10,627.92

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.17	0.24	0.10	0.00	0.00
Short term debt to equity ratio	0.15	0.16	--	--	0.00
Current Ratio	2.48	1.43	2.09	4.14	7.39
Quick Ratio	1.38	0.82	1.37	3.12	5.46
Interest Coverage	10.26	9.96	21.42	140.86	419.57

	Unichem Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	37.63	27.84	26.76	42.05	43.63
Asset Turnover	0.61	1.07	0.79	0.65	0.49
Receivable days	133.23	88.68	77.32	144.58	169.86
Inventory Days	162.76	84.11	80.83	96.67	97.92
Payable days	145.35	176.65	125.94	135.45	159.68
Cash Conversion Cycle	150.64	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.